Supriya Lifescience Limited (SUPRIYA) AI Stock Analysis

• Market Cap: ₹55.31B
• Dividend Yield: 0.13%
• Average Volume (3M): 18.01K
• Price to Earnings (P/E): 30.3
• Beta (1Y): 1.27
• Revenue Growth: 14.35%
• EPS Growth: 15.79%
• Country: IN
• Employees: 448
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 6.30
• Shares Outstanding: 80,482,800
• 10 Day Avg. Volume: 18,341
• 30 Day Avg. Volume: 18,009
• PEG Ratio: 0.54
• Price to Book (P/B): 5.91
• Price to Sales (P/S): 8.46
• P/FCF Ratio: 578.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: ₹773.00 ▲(2.93% Upside)

Supriya Lifescience's strong financial performance is the most significant factor, supported by robust revenue growth and profitability. Technical analysis indicates bullish momentum, though caution is advised due to overbought signals. Valuation metrics suggest potential overvaluation, which tempers the overall score.

Positive Factors

Revenue & Margin Trajectory

Sustained revenue doubling and rising net margin signal durable demand for the company’s API portfolio and improving cost control. This trend supports scalable profitability, funds reinvestment in capacity or R&D, and reduces dependence on short-term pricing cycles over the medium term.

Balance Sheet Strength

A materially stronger equity base and sharply reduced leverage enhance financial resilience, lower refinancing and interest risk, and increase flexibility to fund capex, acquisitions, or weather industry cycles without pressuring operations or cash flow over the coming months.

Improving Cash Generation

Conversion of profits into positive free cash flow and robust operating cash generation indicate operational cash efficiency. This strengthens the company’s ability to fund working capital, reduce debt, and invest in manufacturing capacity or compliance initiatives, supporting durable growth.

Negative Factors

Regulatory & Quality Dependence

As an API manufacturer, the business is structurally exposed to regulatory approvals and quality audits across export markets. Adverse inspection outcomes or changing regulatory standards can interrupt supply, increase compliance costs, or restrict market access, posing sustained operational risk.

Free Cash Flow Volatility

While FCF turned positive in 2025, historical swings indicate uneven investment and capex timing. This volatility reduces predictability for sustained capex, dividends or continued de‑leveraging, and may force management to prioritize short-term liquidity over long-term strategic projects intermittently.

Limited Customer/Geography Disclosure

Lack of disclosure on customer concentration and geographic revenue mix obscures structural durability of sales. If revenue is reliant on a few customers or regions, contract loss or regional regulatory shifts could materially impact results without clear visibility into mitigation or diversification plans.

Supriya Lifescience Limited Business Overview & Revenue Model

Company Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, anti–hypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

How the Company Makes Money

Supriya Lifescience Limited generates revenue primarily through the sale of its active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies. The company’s revenue model is driven by both domestic and international sales, with significant exports contributing to its earnings. Key revenue streams include contracts with large pharmaceutical manufacturers and partnerships that enable SUPRIYA to supply specialized APIs for various therapeutic applications. Additionally, the company benefits from economies of scale in production and a strong focus on research and development, which allows it to introduce new products and maintain competitive pricing. Strategic collaborations with other industry players and adherence to strict regulatory standards also enhance its market presence and profitability.

Supriya Lifescience Limited Financial Statement Overview

Summary

Supriya Lifescience exhibits a robust financial position with strong growth in revenue and profitability, supported by sound balance sheet metrics and improving cash flow management. The company's strategic focus on reducing leverage and enhancing equity has positioned it well for future growth, though attention to cash flow stability will be beneficial.

Income Statement

Supriya Lifescience has demonstrated strong income statement performance with robust revenue growth, increasing from ₹3,116 million in 2020 to ₹6,965 million in 2025. Net Profit Margin improved from 23.5% in 2020 to 27.0% in 2025, indicating enhanced profitability. However, the Gross Profit Margin slightly decreased from 47.8% in 2020 to 55.2% in 2025, suggesting cost efficiency improvements. Consistent growth in EBIT and EBITDA margins further highlight the company's operational effectiveness.

Balance Sheet

The balance sheet is strong with a high Equity Ratio, improving from 44.3% in 2020 to 89.6% in 2025, indicating a solid equity base. The Debt-to-Equity Ratio has significantly reduced, showcasing decreased leverage and financial risk. Return on Equity remains healthy, bolstered by consistent net income growth. The company's prudent financial management is evident in its reduced liabilities and increased equity over the years.

Cash Flow

Supriya Lifescience shows a positive trajectory in cash flow management, with Free Cash Flow turning positive in 2025 after a negative trend. Operating Cash Flow compared to Net Income is strong, indicating efficient cash generation from operations. However, fluctuations in Free Cash Flow over the years highlight potential volatility in capital expenditures and investment strategies.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.81B	6.96B	5.70B	4.51B	5.19B	3.85B
Gross Profit	4.35B	3.84B	2.80B	2.80B	2.89B	2.34B
EBITDA	2.60B	2.71B	1.84B	1.37B	2.22B	1.77B
Net Income	1.78B	1.88B	1.19B	898.57M	1.52B	1.24B
Balance Sheet
Total Assets	0.00	11.12B	9.21B	8.20B	7.35B	4.46B
Cash, Cash Equivalents and Short-Term Investments	791.54M	791.54M	749.56M	1.58B	2.25B	864.27M
Total Debt	0.00	53.80M	54.88M	224.68M	274.15M	721.94M
Total Liabilities	-9.97B	1.16B	1.06B	1.21B	1.19B	1.77B
Stockholders Equity	9.97B	9.97B	8.15B	6.99B	6.16B	2.69B
Cash Flow
Free Cash Flow	0.00	101.89M	-323.48M	-422.13M	-111.03M	316.89M
Operating Cash Flow	0.00	1.73B	1.13B	661.87M	488.01M	799.30M
Investing Cash Flow	0.00	-1.62B	-1.74B	-1.33B	-598.22M	-468.01M
Financing Cash Flow	0.00	-65.47M	-223.59M	-97.77M	1.50B	-145.16M

Supriya Lifescience Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 751.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Negative. The current price of 751 is above the 20-day moving average (MA) of 712.06, above the 50-day MA of 730.85, and above the 200-day MA of 708.99, indicating a bearish trend. The MACD of -18.12 indicates Positive momentum. The RSI at 37.75 is Neutral, neither overbought nor oversold. The STOCH value of 32.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SUPRIYA.

Supriya Lifescience Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	75 Outperform	₹55.31B	30.33	―	0.13%	14.35%	15.79%
SEQUENT	58 Neutral	₹94.51B	125.19	―	―	14.39%	152.14%
AARTIDRUGS	57 Neutral	₹33.79B	16.68	―	0.24%	4.08%	31.52%
GUFICBIO	57 Neutral	₹31.20B	54.82	―	0.03%	7.78%	-34.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPARC	44 Neutral	₹46.03B	-17.02	―	―	-0.82%	34.67%
SUVEN	43 Neutral	₹38.85B	-13.39	―	―	―	―

Supriya Lifescience Limited Corporate Events

Supriya Lifescience Closes Trading Window Ahead of Q3 FY26 Results

Supriya Lifescience Limited has announced the closure of its trading window for company securities for all insiders and designated persons, including their immediate relatives, in line with SEBI (Prohibition of Insider Trading) Regulations, 2015 and its internal code of conduct. The window will remain closed from January 1, 2026 until 48 hours after the company announces its unaudited financial results for the quarter and nine months ended December 31, 2025, underscoring its adherence to governance norms and insider trading safeguards, with the date of the board meeting to approve these results to be communicated later to the market.

Supriya Lifescience Schedules Earnings Call to Discuss Financial Performance

Supriya Lifescience Limited has announced an upcoming earnings call scheduled for November 13, 2025, to discuss its operational and financial performance for the quarter and half-year ending September 30, 2025. This call is crucial for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting investor decisions and market positioning.